TeamDrive
RUS

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

22 June 2015

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

Full video is published at Vedomodsti web-site

According to Leonid Melamed, “The time of uncertainty is exactly the time when management should make important decisions both tactical and strategical that are usually postponed in other times or at least realized in a milder way. This is the right time to allocate internal resources aimed to ensure competitive advantages and to cut down the resources spent on the products, processes and areas that do not bring any competitive value in tactical viewpoint. Such periods are the time to reallocate strategic investments in something that will provide competitive value in 3 to 5 years when stability will come in place of uncertainty. Business model also must be changed, if necessary.

In other words, hard times create a welcomed opportunity for drastic changes that were difficult to realize under regular circumstances.”

In hard times, each business unit of the company is a key point. Such circumstances act as a rich soil to grow brilliant ideas and define the company’s future development. And only highly coordinated operation of all business units may lead the company to a success.

The Vedomosti’s FocusForum Conference will take place June 25, 2015, and bring together various experts who will share their ideas and valuable experience and try to identify an action plan for the future. General Managers, Heads of Business Development, HR, Marketing, Advertising and PR will introduce their business cases and strategies during panel discussions, presentations and unofficial personal meetings.

FocusForum web-site


Previous publication Next publication

Media Center

  • 22 February 2018

    Korea pools patient data to enable digital health schemes

    South Korea is consolidating hospital medical data into a single 10 million-patient repository. The goal is to use Korea’s established medical IT system to build a resource that supports digital health initiatives and the development of new drugs and devices.

  • 21 February 2018

    Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

    Pfizer hasn't gained much market share with Inflectra, its biosimilar of Johnson & Johnson's Remicade, since its U.S. launch back in 2016. The company's CEO Ian Read recently said Inflectra is picking up increased commercial coverage, but an analyst figures the biosimilar's challenges aren't likely to let up this year. 

  • 20 February 2018

    Using stem cells to generate an immune attack against cancer

    Induced pluripotent stem cells (iPSCs) have the power to transform into any cell in the body, making them a prime candidate for regenerative medicine. But can they also teach the immune system to recognize and attack cancer?

  • 20 February 2018

    Russians develop advanced multiple myeloma drug candidate

    Hemopharm, a Russian biotech company, is developing a drug candidate that might help multiple myeloma patients. The new Hemopharm solution is expected to evolve to be such a drug. No direct competition has been reported so far in the global pharmaceutical market. The drug candidate is a humanized antibody with purportedly outstanding anti-tumor activity and low toxicity with proven in vivo efficacy.

Read more